<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ren Fail</journal-id><journal-id journal-id-type="iso-abbrev">Ren Fail</journal-id><journal-title-group><journal-title>Renal Failure</journal-title></journal-title-group><issn pub-type="ppub">0886-022X</issn><issn pub-type="epub">1525-6049</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38946159</article-id><article-id pub-id-type="pmc">PMC467090</article-id>
<article-id pub-id-type="doi">10.1080/0886022X.2024.2371055</article-id><article-id pub-id-type="publisher-id">2371055</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cardio-renal Physiology and Disease Processes</subject></subj-group></article-categories><title-group><article-title>Causal relationship between <italic toggle="yes">Helicobacter pylori</italic> infection and IgA nephropathy: a bidirectional two-sample mendelian randomization study</article-title><alt-title alt-title-type="left-running-head">S. Jing et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-4888-4457</contrib-id><name><surname>Jing</surname><given-names>Shuhui</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Ling</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-2694-7603</contrib-id><name><surname>Li</surname><given-names>Jiaxing</given-names></name><xref rid="AF0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Juan</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4421-011X</contrib-id><name><surname>Qiao</surname><given-names>Xi</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0003" ref-type="aff">c</xref><xref rid="AN0001" ref-type="corresp"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Nephrology, Second Hospital of Shanxi Medical University</institution>, <city>Taiyuan</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF0002"><label>b</label><institution>Shanxi Kidney Disease Institute</institution>, <city>Taiyuan</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF0003"><label>c</label><institution>Kidney Research Center of Shanxi Medical University</institution>, <city>Taiyuan</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF0004"><label>d</label><institution>Department of General Surgery, The Second Hospital of Shanxi Medical University</institution>, <city>Taiyuan</city>, <country>People&#x02019;s Republic of China</country></aff></contrib-group><author-notes><fn id="AUFN1"><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="10.1080/0886022X.2024.2371055" ext-link-type="doi">https://doi.org/10.1080/0886022X.2024.2371055</ext-link>.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Xi Qiao <email xlink:href="mailto:qiaoxi7347@vip.163.com">qiaoxi7347@vip.163.com</email>
<institution>Department of Nephrology, Second Hospital of Shanxi Medical University</institution>, <city>Taiyuan</city>, <country>People&#x02019;s Republic of China</country>; <institution>Shanxi Kidney Disease Institute</institution>, <city>Taiyuan</city>, <country>People&#x02019;s Republic of China</country>; <institution>Kidney Research Center of Shanxi Medical University</institution>, <city>Taiyuan</city>, <country>People&#x02019;s Republic of China</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>6</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>6</month><year>2024</year></pub-date><volume>46</volume><issue>2</issue><elocation-id>2371055</elocation-id><pub-history><event event-type="received"><date><day>1</day><month>5</month><year>2024</year></date></event><event event-type="revised"><date><day>2</day><month>6</month><year>2024</year></date></event><event event-type="accepted"><date><day>17</day><month>6</month><year>2024</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>26</day><month>6</month><year>2024</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>26</day><month>6</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IRNF_46_2371055.pdf"/><abstract><title>Abstract</title><p>IgA nephropathy (IgAN) is one of the most common primary glomerulonephritis, and serum <italic toggle="yes">Helicobacter pylori</italic> (<italic toggle="yes">H. pylori</italic>) antibody levels are increased in patients with IgA N, but the role of <italic toggle="yes">H. pylori</italic> infection in the pathogenesis of IgAN is unclear. In this study, we investigated whether there is a causal relationship and reverse causality between IgAN and <italic toggle="yes">H. pylori</italic> infection by using a bidirectional two-sample Mendelian randomization (MR) analysis. This study was estimated using inverse variance weighted (IVW), MR-Egger and weighted median methods, with the IVW method having the strongest statistical efficacy. Seven common serum <italic toggle="yes">H. pylori</italic> antibodies were selected as exposure factors for positive MR analysis. The results showed that there was no evidence of a causal relationship between <italic toggle="yes">H. pylori</italic> infection and IgAN. Reverse MR analysis showed that there was also no evidence that the occurrence of IgAN leads to an increased risk of <italic toggle="yes">H. pylori</italic> infection.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>IgA nephropathy</kwd><kwd><italic toggle="yes">Helicobacter pylori</italic> infection</kwd><kwd>Mendelian randomization</kwd><kwd>Genome-wide association studies</kwd><kwd>causality</kwd></kwd-group><support-group><funding-group><award-group><funding-source>
<institution-wrap><institution>the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province</institution></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Shanxi Scholarship Council of China</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100003398</institution-id></institution-wrap>
</funding-source><award-id>2020-186</award-id></award-group><award-group><funding-source>
<institution-wrap><institution>the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province</institution></institution-wrap>
</funding-source><award-id>2017-29</award-id></award-group><funding-statement>This work was supported by the Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province [Grant no. 2017-29] (<bold>Additional file2</bold>), and a Research Project Supported by Shanxi Scholarship Council of China [2020-186] (<bold>Additional file3</bold>).</funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="5"/><page-count count="10"/><word-count count="6617"/></counts></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S0001"><title>Introduction</title><p><italic toggle="yes">Helicobacter pylori</italic> (<italic toggle="yes">H. pylori</italic>) is a gram-negative bacterium that colonizes the mucus layer of the human stomach and is usually transmitted during childhood. If left untreated, <italic toggle="yes">H. pylori</italic> infections can persist throughout life [<xref rid="CIT0001" ref-type="bibr">1</xref>]. <italic toggle="yes">H. pylori</italic> infections are not only involved in the pathogenesis of gastritis and peptic ulcers. Still, they are also inextricably linked to renal diseases [<xref rid="CIT0002" ref-type="bibr">2&#x02013;4</xref>].</p><p>IgA nephropathy(IgAN) is one of the most common forms of glomerulonephritis worldwide [<xref rid="CIT0005" ref-type="bibr">5</xref>], affecting mainly young adults in their 20s and 40s [<xref rid="CIT0006" ref-type="bibr">6</xref>]. Patients present with microscopic hematuria, proteinuria, nephrotic syndrome, or acute progressive glomerulonephritis[<xref rid="CIT0007" ref-type="bibr">7</xref>]. Between 30% and 45% of patients may progress to end-stage renal disease within 20 to 25&#x02009;years of diagnosis of IgAN [<xref rid="CIT0008" ref-type="bibr">8&#x02013;10</xref>].</p><p>Evidence from epidemiology suggests that <italic toggle="yes">H. pylori</italic> infection is associated with an increased risk of developing kidney disease, with a cross-sectional study showing <italic toggle="yes">H. pylori</italic> positivity in up to 50% of 293 patients undergoing kidney transplantation [<xref rid="CIT0002" ref-type="bibr">2</xref>]. A study from Pan W suggested that <italic toggle="yes">H. pylori</italic> infection may be a risk factor for kidney injury, which was positively correlated with altered albumin/creatinine ratio, which decreased after <italic toggle="yes">H. pylori</italic> eradication [<xref rid="CIT0003" ref-type="bibr">3</xref>], and a prospective study found that IgA was detected in 38 out of 43 (88.4%) patients with tonsil <italic toggle="yes">H. pylori</italic> positivity, and it was hypothesized that <italic toggle="yes">H. pylori</italic> is one of the causative antigens of IgAN [<xref rid="CIT0011" ref-type="bibr">11</xref>]. However, the results of most observational studies are not entirely consistent, and a cross-sectional study did not find any significant difference in the prevalence of proteinuria between the <italic toggle="yes">H. pylori</italic>-infected and non-infected groups [<xref rid="CIT0012" ref-type="bibr">12</xref>]. In addition, multiple linear regression analysis showed that there was still no significant difference in eGFR and odds of proteinuria reduction between <italic toggle="yes">H. pylori</italic>-positive and negative subjects. Liu XZ et&#x000a0;al. showed the experimental results that type I <italic toggle="yes">H. pylori</italic>-infected patients showed a tendency toward lower eGFR but did not reach statistical significance [<xref rid="CIT0013" ref-type="bibr">13</xref>].</p><p>Conventional studies are inevitably subject to a variety of confounding factors and reverse causality bias. Therefore, it remains unknown whether <italic toggle="yes">H. pylori</italic> infection contributes to the development of IgAN. Although several studies have shown a correlation between <italic toggle="yes">H. pylori</italic> and IgAN, it may be affected by confounding factors such as age, gender, hypertension, diabetes, smoking, hyperlipidemia, etc., and thus it is crucial to study the correlation between <italic toggle="yes">H. pylori</italic> infection and IgAN. With the exponential growth and wide availability of genetic data, MR as an epidemiologic study reduces confounding strengthens exposure-outcome associations, and avoids reverse causation. In this study, we analyzed MR with seven indicators associated with <italic toggle="yes">H. pylori</italic> infection (Anti-<italic toggle="yes">H. pylori</italic> IgG, <italic toggle="yes">H. pylori</italic> CagA antibody, <italic toggle="yes">H. pylori</italic> CAT antibody, <italic toggle="yes">H. pylori</italic> GroEL antibody, <italic toggle="yes">H. pylori</italic> OMP antibody, <italic toggle="yes">H. pylori</italic> UreA antibody, and <italic toggle="yes">H. pylori</italic> VacA antibody) as exposure factors and IgAN as outcome. To further confirm whether there was a reverse causality between <italic toggle="yes">H. pylori</italic> infection and IgAN, we also performed reverse MR analysis (<xref rid="F0001" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F0001"><label>Figure 1.</label><caption><p>An investigation of the causal relationship between <italic toggle="yes">H. pylori</italic> infection and IgAN.</p></caption><graphic xlink:href="IRNF_A_2371055_F0001_C" content-type="color" position="float"/></fig></sec><sec sec-type="materials" disp-level="1" id="S0002"><title>Materials and methods</title><sec disp-level="2" id="S0002-S2001"><title>Study design and hypothesis</title><p>Mendelian randomization(MR), which uses single nucleotide polymorphisms(SNPs) as instrumental variables(IVs), is a method of causal inference based on genetic variation. Its basic principle is to use the effect of randomly assigned genotypes on phenotype in nature to infer the effect of genetic biological factors on disease. Since the genes are assigned following the principle of random assignment and the mutations precede the onset of the disease, MR can be regarded as a natural randomized controlled trial(RCT). Compared with conventional studies, the interference of reverse causality and confounding factors on the accuracy of results can be avoided. The present study is a bidirectional MR study, and MR must fulfill three major assumptions: 1. the assumption of correlation (the selected IVs are strongly correlated with exposure, with <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;1e-5 and <italic toggle="yes">F</italic>&#x02009;&#x0003e;&#x02009;10); 2. the assumption of independence (there is no correlation between the IVs and the outcome); and 3. the assumption of exclusivity (the IVs cannot influence the outcome through confounders other than exposure) (<xref rid="F0002" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="F0002"><label>Figure 2.</label><caption><p>Schematic representation of the bidirectional MR study on the causal relationship between <italic toggle="yes">H. pylori</italic> infection and IgAN. IVs: instrument variants; SNP: single-nucleotide polymorphisms; IgAN, IgA nephropathy.</p></caption><graphic xlink:href="IRNF_A_2371055_F0002_C" content-type="color" position="float"/></fig></sec><sec disp-level="2" id="S0002-S2002"><title>Exposure GWAS data source</title><p>Suitable genetic variants were selected as IVs for <italic toggle="yes">H. pylori</italic> infection, and the genetic background of all cases and controls was of European ancestry, which reduces bias due to race-related confounders. A search of the IEU database (<ext-link xlink:href="https://gwas.mrcieu.ac.uk/" ext-link-type="uri">https://gwas.mrcieu.ac.uk/</ext-link>) for <italic toggle="yes">H. pylori</italic>-related phenotypes revealed that the seven phenotypes used in the analysis of exposure factors for this MR all came from the same study. A total of 8735 individual UK participants were enrolled in this study, with 55.9% female and 44.1% male participants, and the median age (interquartile range) at enrollment in the UKB was 58 (51&#x02013;64) years, which analyzed seropositivity rates for 13 pathogen-related indicators. Anti-<italic toggle="yes">H. pylori</italic> IgG seropositivity included a total of 8,735 individuals containing 9,170,312 SNPs, <italic toggle="yes">H. pylori</italic> CagA antibody included 985 individuals containing 9,165,056 SNPs, <italic toggle="yes">H. pylori</italic> CAT antibody included 1,558 individuals containing 9,167,570 SNPs, <italic toggle="yes">H. pylori</italic> GroEL antibody included 2,716 individuals containing 9,172,299 SNPs, <italic toggle="yes">H. pylori</italic> OMP antibody incorporated 2640 individuals containing 9,167,440 SNPs, <italic toggle="yes">H. pylori</italic> UREA antibody incorporated 2251 individuals containing 9,170,248 SNPs, and <italic toggle="yes">H. pylori</italic> VacA antibody incorporated 1571 individuals containing 9,178,635 SNPs (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="t0001"><label>Table 1.</label><caption><p>Details of the GWAS data in this study.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Exposure and Outcome</th><th align="center">Source</th><th align="center">Sample size</th><th align="center">Ancestry</th><th align="center">Year</th><th align="center">Numbers of SNPs</th><th align="center">Access Link</th></tr></thead><tbody valign="top"><tr><td align="left">Anti-<italic toggle="yes">H. pylori</italic> IgG</td><td align="left">UKB</td><td align="char" char=".">8735</td><td align="left">European</td><td align="char" char=".">2020</td><td align="char" char=".">9,170,312</td><td align="left"><ext-link xlink:href="https://gwas.mrcieu.ac" ext-link-type="uri">https://gwas.mrcieu.ac</ext-link>.<break/>uk/datasets/ebi-a-GCST90006910</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CagA antibody</td><td align="left">UKB</td><td align="char" char=".">985</td><td align="left">European</td><td align="char" char=".">2020</td><td align="char" char=".">9,165,056</td><td align="left"><ext-link xlink:href="https://gwas.mrcieu.ac" ext-link-type="uri">https://gwas.mrcieu.ac</ext-link>.<break/>uk/datasets/ebi-a-GCST90006911</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CAT antibody</td><td align="left">UKB</td><td align="char" char=".">1558</td><td align="left">European</td><td align="char" char=".">2020</td><td align="char" char=".">9,167,570</td><td align="left"><ext-link xlink:href="https://gwas.mrcieu.ac" ext-link-type="uri">https://gwas.mrcieu.ac</ext-link>.<break/>uk/datasets/ebi-a-GCST90006912</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> GroEL antibody</td><td align="left">UKB</td><td align="char" char=".">2716</td><td align="left">European</td><td align="char" char=".">2020</td><td align="char" char=".">9,172,299</td><td align="left"><ext-link xlink:href="https://gwas.mrcieu.ac" ext-link-type="uri">https://gwas.mrcieu.ac</ext-link>.<break/>uk/datasets/ebi-a-GCST90006913</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> OMP antibody</td><td align="left">UKB</td><td align="char" char=".">2640</td><td align="left">European</td><td align="char" char=".">2020</td><td align="char" char=".">9,167,440</td><td align="left"><ext-link xlink:href="https://gwas.mrcieu.ac" ext-link-type="uri">https://gwas.mrcieu.ac</ext-link>.<break/>uk/datasets/ebi-a-GCST90006914</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> UREA antibody</td><td align="left">UKB</td><td align="char" char=".">2251</td><td align="left">European</td><td align="char" char=".">2020</td><td align="char" char=".">9,170,248</td><td align="left"><ext-link xlink:href="https://gwas.mrcieu.ac" ext-link-type="uri">https://gwas.mrcieu.ac</ext-link>.<break/>uk/datasets/ebi-a-GCST90006915</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> VacA antibody</td><td align="left">UKB</td><td align="char" char=".">1571</td><td align="left">European</td><td align="char" char=".">2020</td><td align="char" char=".">9,178,635</td><td align="left"><ext-link xlink:href="https://gwas.mrcieu.ac" ext-link-type="uri">https://gwas.mrcieu.ac</ext-link>.<break/>uk/datasets/ebi-a-GCST90006916</td></tr><tr><td align="left">IgAN</td><td align="left">FinnGen;<break/>UKB;BBJ</td><td align="char" char=".">477,784</td><td align="left">European</td><td align="char" char=".">2021</td><td align="char" char=".">24,182,646</td><td align="left">
<ext-link xlink:href="https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90018866" ext-link-type="uri">https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90018866</ext-link>
</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>SNP: single-nucleotide polymorphisms; IgAN: IgA nephropathy.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0002-S2003"><title>Outcome GWAS data sources</title><p>Genetic variants associated with IgAN were extracted from the GWAS study, which included 15,587 cases and 462,197 controls, totaling 24,182,646 SNPs, and all participants were of European ancestry. Instrumental SNPs were associated with IgAN at the genome-wide significance (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;1e-5).</p></sec><sec disp-level="2" id="S0002-S2004"><title>Selection of IVs</title><p>In this study, IVs were rigorously screened for SNPs. SNPs with genome-wide association (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;1e-5) were extracted, and SNPs with weak IVs for exposure were excluded. in addition, the F statistic indicated the strength of association between the IVs and the exposure factors, and SNPs with <italic toggle="yes">F</italic>&#x02009;&#x0003e;&#x02009;10 were selected. Then, chain-unbalanced SNPs were excluded (r^2&#x02009;&#x0003c;&#x02009;0.001, <italic toggle="yes">k</italic>&#x02009;&#x0003e;&#x02009;10,000kb) to ensure that the SNPs were independent. Selected SNPs that are strongly correlated with exposure, independent of each other. Then remove the SNPs that are strongly correlated with the outcome from these selected SNPs. Next, these SNPs should be sequentially searched using PhenoScannerV2 and LDtrait to identify and remove confounding factors that affect the occurrence of IgAN, such as age, weight, hypertension, proteinuria, dental caries, periodontitis, tonsillitis, and other infections, including respiratory pathogens (e.g., <italic toggle="yes">Mycoplasma pneumoniae</italic>, herpes virus, influenza), gut microbiota. Remove SNPs associated with confounding factors prior to conducting MR analysis to minimize their interference with results. If there were no corresponding SNPs in the outcome, a proxy SNP could be found in the outcome based on the LDR^2&#x02009;&#x0003e;&#x02009;0.8. Finally, the exposure SNPs were synergized with the outcome SNPs to eliminate palindromic sequences and incompatible SNPs.</p></sec><sec disp-level="2" id="S0002-S2005"><title>MR analysis</title><p>Forward MR analysis was performed using <italic toggle="yes">H. pylori</italic>-related IVs as the exposure and IgAN as the outcome to detect the causal relationship between <italic toggle="yes">H. pylori</italic> infection and IgAN at the gene level. Reverse MR analysis was performed using SNPs strongly associated with IgAN as IVs and seven phenotypes associated with <italic toggle="yes">H. pylori</italic> infection as outcomes to explore whether there was a causal relationship between IgAN and <italic toggle="yes">H. pylori</italic> infection at the gene level.</p><p>In the bidirectional MR analysis, the IVW method had the highest statistical efficacy, and IVW was used as the primary analysis method, with MR-Egger and weighted median methods as complementary methods for MR analysis.</p><p>Heterogeneity and horizontal pleiotropy of IVs may lead to bias in MR results, and the selection of appropriate statistical methods is of particular importance. Before analyzing the data, heterogeneity among IVs was assessed using the Cochranes&#x02019; Q test and the I<sup>2</sup> test. The presence of heterogeneity is indicated by a <italic toggle="yes">p</italic> value &#x0003e; 0.05, while a <italic toggle="yes">p</italic> value &#x0003c; 0.05 suggests the absence or lesser degree of heterogeneity. The I<sup>2</sup> statistic was calculated using the formula I<sup>2</sup> = 100% &#x000d7; (Q &#x02013;df)/Q, reflecting the proportion of the heterogeneity component in the total variance of the effect sizes as a complement to the sensitivity analysis. An I<sup>2</sup> value &#x0003e; 50% indicates more pronounced heterogeneity. If no heterogeneity was detected, the analysis was conducted using either the IVW fixed-effects model or the IVW random-effects model. When heterogeneity was present and no horizontal pleiotropy was detected, the analysis was conducted using the IVW random-effects model. Horizontal pleiotropy was examined using the MR-Egger intercept test, with statistical significance determined by the <italic toggle="yes">p</italic> value of the intercept term. A <italic toggle="yes">p</italic> value &#x0003e; 0.05 indicates no horizontal pleiotropy, suggesting reliable results. When a <italic toggle="yes">p</italic> value &#x0003c; 0.05, indicating horizontal pleiotropy, the MR-PRESSO global test method was further applied to correct for it by eliminating outlier variables. Outlier-corrected and leave-one-out methods were employed to detect outliers. If outliers were identified, the outlier SNPs needed to be removed and the analysis repeated. Additionally, the Raw test from the MR-PRESSO analysis can serve as a complement to the primary IVW outcome. It is generally accepted that a causal relationship between exposure and outcome may exist if the MR analysis results are significant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05), and the results are considered robust when horizontal pleiotropy is absent. We applied the MR-Steiger analysis to monitor the direction of potential causality between <italic toggle="yes">H. pylori</italic> infection and IgAN risk and used reverse MR analysis to further validate the absence of reverse causality between <italic toggle="yes">H. pylori</italic> infection and IgAN.</p></sec><sec disp-level="2" id="S0002-S2006"><title>Statistical processing</title><p>All analyses were performed using the &#x02018;Two Sample MR&#x02019; (version 0.5.11) package in R software (version 4.2.3). Results are presented as odds ratio (OR) and corresponding 95% confidence interval (CI), with a difference of <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 considered statistically significant. All analyses were based on publicly available data and did not require ethical approval.</p></sec></sec><sec sec-type="results" disp-level="1" id="S0003"><title>Results</title><sec disp-level="2" id="S0003-S2001"><title>Selection of IVs</title><p>In the forward MR analysis with <italic toggle="yes">H. pylori</italic> infection as the exposure factor, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;1e-5, <italic toggle="yes">F</italic>&#x02009;&#x0003e;&#x02009;10 between the IVs and the exposure factor was used as the screening condition, and chain imbalance and palindromic alleles were removed. <italic toggle="yes">H. pylori</italic>-IgG screened 17 SNPs as instrumental variables and excluded those that might be associated with confounding factors: rs10488625, rs11139381, rs11201988, rs17232730. A total of 13 SNPs were retained. <italic toggle="yes">H. pylori</italic> CagA antibody screened 24 SNPs and excluded SNPs related to confounding factors: rs1571534, rs3998182, rs56264437, rs6530847, leaving 20 SNPs retained. <italic toggle="yes">H. pylori</italic>-CAT screened a total of 16 SNPs, excluding those related to confounding factors: rs2946532, rs6456714, with 14 SNPs remaining. <italic toggle="yes">H. pylori</italic> GroEL antibody screened 9 SNPs with no SNPs associated with confounders. <italic toggle="yes">H. pylori</italic> OMP antibody screened 16 SNPs, removing those related to confounding factors: rs3104361, and retaining 15 SNPs. <italic toggle="yes">H. pylori</italic> UreA antibody screened 24 SNPs, removing confounding-related SNPs: rs9273219, rs111488068, and retaining 22 SNPs. <italic toggle="yes">H. pylori</italic> VacA antibody screened 24 SNPs, removing SNPs. rs11844235, and retaining 23 SNPs. These phenotypes were analyzed by MR as exposure factor versus outcome IgAN, respectively. In the reverse MR analysis, with IgAN as the exposure factor and <italic toggle="yes">H. pylori</italic>-associated antibody as the outcome, the same method was used to identify the instrumental variables. <italic toggle="yes">H. pylori</italic> CagA antibody and <italic toggle="yes">H. pylori</italic> VacA antibody screened 32 SNPs each, and 5 SNPs that might be associated with confounding factors were deleted: rs10786766, rs2058367, rs2524075, rs4434650, rs9266216, with 27 SNPs retained as instrumental variables. The remaining <italic toggle="yes">H. pylori</italic> infection-associated serum antibodies were screened for 33 SNPs each, and 5 SNPs associated with confounding were similarly deleted: rs10786766, rs2058367, rs2524075, rs4434650, rs9266216, with 28 SNPs remaining for analysis by reverse MR.</p></sec><sec disp-level="2" id="S0003-S2002"><title>Forward MR analysis</title><p>After the rigorous screening of IVs, the Cochran Q test results for both the IVW and MR-Egger methods indicated that some heterogeneity for <italic toggle="yes">H. pylori</italic> CAT antibody as an exposure factor. The Cochran Q test result of MR-Egger method was <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.009, with an I<sup>2</sup> of 55.1%, and for the IVW method, it was <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.011, with an I<sup>2</sup> of 52.5%. These results were analyzed using an IVW random-effects model. Horizontal pleiotropy was assessed using the MR-Egger intercept test and the MR-PRESSO global test; all <italic toggle="yes">p</italic> values were &#x0003e; 0.05, indicating no horizontal pleiotropy and thus the results are considered reliable. The MR-Egger regression results were further validated using outlier-corrected and leave-one-out methods, which showed no evidence of outliers. Additionally, the Raw test from the MR-PRESSO served as a complement to the primary IVW outcome, with a <italic toggle="yes">p</italic> value &#x0003e; 0.05 (<xref rid="t0002" ref-type="table">Table 2</xref>), further validating the lack of evidence for a causal association between <italic toggle="yes">H. pylori</italic> infection and IgAN. Forward MR analysis of each of these seven <italic toggle="yes">H. pylori</italic> infection-associated phenotypes as exposure factors showed no evidence that any of the genetic variations.</p><table-wrap position="float" id="t0002"><label>Table 2.</label><caption><p>Results of the sensitivity analysis between <italic toggle="yes">H. pylori</italic> infection and IgAN estimated by the forward MR method.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="3" align="left">Exposure</th><th colspan="7" align="center">Heterogeneity<hr/></th><th colspan="3" align="center">Horizontal pleiotropy<hr/></th><th colspan="2" align="center">&#x000a0;<hr/></th></tr><tr><th colspan="2" align="center">MR-Egger<hr/></th><th colspan="2" align="center">IVW<hr/></th><th colspan="3" align="center">MR-Egger regression<hr/></th><th colspan="3" align="center">MR-PRESSO<hr/></th><th colspan="2" align="center">steiger test<hr/></th></tr><tr><th align="center">Q</th><th align="center">I<sup>2</sup></th><th align="center">Q</th><th align="center">I<sup>2</sup></th><th align="center">Intercept</th><th align="center">SE</th><th align="center">
<italic toggle="yes">p</italic>
</th><th align="center">
<italic toggle="yes">p</italic>
</th><th align="center">
<italic toggle="yes">Raw p</italic>
</th><th align="center">Outlier-corrected</th><th align="center">
<italic toggle="yes">pval</italic>
</th><th align="center">dir</th></tr></thead><tbody valign="top"><tr><td align="left">Anti<italic toggle="yes">-H. pylori</italic> IgG</td><td align="char" char=".">0.501</td><td align="char" char=".">0%</td><td align="char" char=".">0.564</td><td align="char" char=".">0%</td><td align="char" char=".">0.007</td><td align="char" char=".">0.014</td><td align="char" char=".">0.611</td><td align="char" char=".">0.571</td><td align="char" char=".">0.078</td><td align="center">NA</td><td align="char" char=".">5.063E-69</td><td align="left">TRUE</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CagA antibody</td><td align="char" char=".">0.387</td><td align="char" char=".">5.6%</td><td align="char" char=".">0.345</td><td align="char" char=".">8.9%</td><td align="char" char=".">0.013</td><td align="char" char=".">0.010</td><td align="char" char=".">0.211</td><td align="char" char=".">0.349</td><td align="char" char=".">0.934</td><td align="center">NA</td><td align="char" char=".">4.165E-129</td><td align="left">TRUE</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CAT antibody</td><td align="char" char=".">0.009</td><td align="char" char=".">55.1%</td><td align="char" char=".">0.011</td><td align="char" char=".">52.5%</td><td align="char" char=".">&#x02212;0.008</td><td align="char" char=".">0.015</td><td align="char" char=".">0.587</td><td align="char" char=".">0.137</td><td align="char" char=".">0.952</td><td align="center">NA</td><td align="char" char=".">5.906E-75</td><td align="left">TRUE</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> GroEL antibody</td><td align="char" char=".">0.149</td><td align="char" char=".">37.2%</td><td align="char" char=".">0.121</td><td align="char" char=".">34.9%</td><td align="char" char=".">0.020</td><td align="char" char=".">0.017</td><td align="char" char=".">0.294</td><td align="char" char=".">0.131</td><td align="char" char=".">0.931</td><td align="center">NA</td><td align="char" char=".">9.891E-39</td><td align="left">TRUE</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> OMP antibody</td><td align="char" char=".">0.236</td><td align="char" char=".">20.0%</td><td align="char" char=".">0.264</td><td align="char" char=".">16.9%</td><td align="char" char=".">0.009</td><td align="char" char=".">0.012</td><td align="char" char=".">0.500</td><td align="char" char=".">0.236</td><td align="char" char=".">0.228</td><td align="center">NA</td><td align="char" char=".">2.251E-81</td><td align="left">TRUE</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> UREA antibody</td><td align="char" char=".">0.589</td><td align="char" char=".">0%</td><td align="char" char=".">0.571</td><td align="char" char=".">0%</td><td align="char" char=".">&#x02212;0.011</td><td align="char" char=".">0.010</td><td align="char" char=".">0.279</td><td align="char" char=".">0.585</td><td align="char" char=".">0.887</td><td align="center">NA</td><td align="char" char=".">4.816E-120</td><td align="left">TRUE</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> VacA antibody</td><td align="char" char=".">0.498</td><td align="char" char=".">0%</td><td align="char" char=".">0.354</td><td align="char" char=".">7.8%</td><td align="char" char=".">&#x02212;0.017</td><td align="char" char=".">0.009</td><td align="char" char=".">0.075</td><td align="char" char=".">0.367</td><td align="char" char=".">0.094</td><td align="center">NA</td><td align="char" char=".">3.779E-138</td><td align="left">TRUE</td></tr></tbody></table></table-wrap><p>The results of the IVW method showed the following odds ratios (ORs) and confidence intervals (CIs) for Anti-<italic toggle="yes">H. pylori</italic> IgG (OR = 0.834; 95% CI, 0.685 to 1.015; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.070), <italic toggle="yes">H. pylori</italic> CagA antibody (OR = 0.999; 95% CI, 0.973 to 1.025; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.933), <italic toggle="yes">H. pylori</italic> CAT antibody (OR = 1.002; 95% CI, 0.950 to 1.057; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.951), <italic toggle="yes">H. pylori</italic> GroEL antibody (OR = 1.003; 95% CI, 0.929 to 1.084; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.929), <italic toggle="yes">H. pylori</italic> OMP antibody (OR = 0.969; 95% CI, 0.923 to 1.018; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.208), <italic toggle="yes">H. pylori</italic> UREA antibody (OR = 0.998; 95% CI, 0.962 to 1.034; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.891), and <italic toggle="yes">H. pylori</italic> VacA antibody (OR = 1.027; 95% CI, 0.997 to 1.058; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.081) (<xref rid="t0003" ref-type="table">Table 3</xref>). There was no statistically significant association between these <italic toggle="yes">H. pylori</italic> antibodies and increased risk of IgAN; the funnel plots of the phenotypic IVW method for all 7 studies were largely symmetric and did not affect the estimated causal effect. Removal of individual SNPs by the leave-one-out method did not significantly alter the overall results, suggesting that the results were stable and reliable (<bold>Additional file1</bold>: <ext-link xlink:href="10.1080/0886022X.2024.2371055" ext-link-type="doi">Figures 1&#x02013;S7</ext-link>). Steiger-MR analyses were used to test the robustness of the causal effect estimates. Steiger-MR found that SNPs explained more of the exposure than the outcome, indicating no reverse causality.</p><table-wrap position="float" id="t0003"><label>Table 3.</label><caption><p>Forward MR of serum <italic toggle="yes">H. pylori</italic> antibodies with IgAN.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Exposure</th><th align="center">Method</th><th align="center">SNPs</th><th align="center">&#x000a0;</th><th align="center">OR(95%CI)</th><th align="center"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody valign="top"><tr><td align="left"><italic toggle="yes">Anti-H. pylori</italic> IgG</td><td align="left">Inverse variance weighted</td><td align="char" char=".">13</td><td rowspan="21" align="left">
<inline-graphic xlink:href="IRNF_A_2371055_ILG0001_B.jpg" content-type="black-white"/>
</td><td align="char" char=".">0.834(0.685&#x02013;1.015)</td><td align="char" char=".">0.070</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">13</td><td align="char" char=".">0.739(0.451&#x02013;1.210)</td><td align="char" char=".">0.255</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">13</td><td align="char" char=".">0.903(0.690&#x02013;1.182)</td><td align="char" char=".">0.456</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CagA antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">20</td><td align="char" char=".">0.999(0.973&#x02013;1.025)</td><td align="char" char=".">0.933</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">20</td><td align="char" char=".">0.964(0.907&#x02013;1.023)</td><td align="char" char=".">0.242</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">20</td><td align="char" char=".">1.016(0.980&#x02013;1.054)</td><td align="char" char=".">0.387</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CAT antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">14</td><td align="char" char=".">1.002(0.950&#x02013;1.057)</td><td align="char" char=".">0.951</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">14</td><td align="char" char=".">1.030(0.920&#x02013;1.054)</td><td align="char" char=".">0.614</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">14</td><td align="char" char=".">1.012(0.953&#x02013;1.074)</td><td align="char" char=".">0.704</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> GroEL antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">9</td><td align="char" char=".">1.003(0.929&#x02013;1.084)</td><td align="char" char=".">0.929</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">9</td><td align="char" char=".">0.919(0.775&#x02013;1.089)</td><td align="char" char=".">0.362</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">9</td><td align="char" char=".">0.990(0.905&#x02013;1.083)</td><td align="char" char=".">0.832</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> OMP antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">15</td><td align="char" char=".">0.969(0.923&#x02013;1.018)</td><td align="char" char=".">0.208</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">15</td><td align="char" char=".">0.934(0.831&#x02013;1.049)</td><td align="char" char=".">0.268</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">15</td><td align="char" char=".">0.981(0.918&#x02013;1.049)</td><td align="char" char=".">0.581</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> UREA antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">22</td><td align="char" char=".">0.998(0.962&#x02013;1.034)</td><td align="char" char=".">0.891</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">22</td><td align="char" char=".">1.044(0.956&#x02013;1.139)</td><td align="char" char=".">0.349</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">22</td><td align="char" char=".">1.009(0.960&#x02013;1.060)</td><td align="char" char=".">0.730</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> VacA antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">23</td><td align="char" char=".">1.027(0.997&#x02013;1.058)</td><td align="char" char=".">0.081</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">23</td><td align="char" char=".">1.081(1.017&#x02013;1.149)</td><td align="char" char=".">0.020</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">23</td><td align="char" char=".">1.015(0.976&#x02013;1.055)</td><td align="char" char=".">0.454</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><p>SNP: single-nucleotide polymorphisms; OR: odds ratio; LCl: lower confidence interval; UCI: upper confidence interval; IgAN: IgA nephropathy.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0003-S2003"><title>Reverse MR analysis</title><p>Inverse MR analysis was performed with IgAN as an exposure factor and <italic toggle="yes">H. pylori</italic> as an outcome, and again negative results were obtained: there was no evidence of a causal relationship between IgAN and <italic toggle="yes">H. pylori</italic> infection. Cochran Q test results and I<sup>2</sup> statistics indicated no significant heterogeneity (all <italic toggle="yes">p</italic>&#x02009;&#x0003e;&#x02009;0.05) in MR analysis using IgAN as exposure and serum <italic toggle="yes">H. pylori</italic> antibodies as outcomes. Horizontal pleiotropy was assessed using the MR-Egger intercept test and the MR-PRESSO global test; the results showed no evidence of horizontal pleiotropy (all <italic toggle="yes">p</italic>&#x02009;&#x0003e;&#x02009;0.05), confirming the reliability of the MR analysis conclusions. The MR-Egger regression results were further validated by using Outlier-corrected and leave-one-out methods. For <italic toggle="yes">H. pylori</italic> VacA antibody, an outlier (rs112048665) was detected; subsequent MR analysis was conducted after its removal. The remaining phenotypes showed no evidence of outliers (<xref rid="t0004" ref-type="table">Table 4</xref>). The IVW results provided no evidence that the occurrence of IgAN leads to increased expression of <italic toggle="yes">H. pylori</italic> antibodies. Anti-<italic toggle="yes">H. pylori</italic> IgG (OR = 0.992; 95% CI 0.954, 1.042; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.759), <italic toggle="yes">H. pylori</italic> CagA antibody (OR = 0.992; 95% CI0.745,1.320; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.955, <italic toggle="yes">H. pylori</italic> CAT antibody (OR = 1.099; 95%CI0.882,1.369; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.402) <italic toggle="yes">H. pylori</italic> GroEL antibody (OR = 1.024; 95%CI0.836,1.254; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.820) <italic toggle="yes">H. pylori</italic> OMP antibody (OR = 0.993; 95%CI0.836-1.181; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.940) <italic toggle="yes">H. pylori</italic> UREA antibody (OR = 1.111; 95%CI0.923-1.337; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.267) <italic toggle="yes">H. pylori</italic> VacA antibody (OR = 0.984; 95%CI0.753,1.284; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.903) (<xref rid="t0005" ref-type="table">Table 5</xref>). The Raw test from the MR-PRESSO analysis, which complements the primary IVW result, had a <italic toggle="yes">p</italic>-value &#x0003e; 0.05, further validating the lack of evidence for a causal association between <italic toggle="yes">H. pylori</italic> infection and IgAN. Funnel plots for all IVW method analyses were largely symmetric and did not affect the estimated causal effect. The overall results remained stable and reliable after the removal of individual SNPs using the leave-one-out method, with no significant change in the outcomes (<bold>Additional file 1:</bold>
<ext-link xlink:href="10.1080/0886022X.2024.2371055" ext-link-type="doi">Figure S8&#x02013;S14</ext-link>).</p><table-wrap position="float" id="t0004"><label>Table 4.</label><caption><p>Results of the sensitivity analysis between <italic toggle="yes">H. pylori</italic> infection and IgAN estimated by the reverse MR method.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="3" align="left">Exposure</th><th colspan="6" align="center">Heterogeneity<hr/></th><th colspan="4" align="center">Horizontal pleiotropy<hr/></th></tr><tr><th colspan="2" align="center">MR-Egger<hr/></th><th colspan="2" align="center">IVW<hr/></th><th colspan="3" align="center">MR-Egger regression<hr/></th><th colspan="3" align="center">MR-PRESSO<hr/></th></tr><tr><th align="center">Q</th><th align="center">I<sup>2</sup></th><th align="center">Q</th><th align="center">I<sup>2</sup></th><th align="center">Intercept</th><th align="center">SE</th><th align="center">
<italic toggle="yes">p</italic>
</th><th align="center">
<italic toggle="yes">p</italic>
</th><th align="center">
<italic toggle="yes">Raw p</italic>
</th><th align="center">Outlier-corrected</th></tr></thead><tbody valign="top"><tr><td align="left">Anti<italic toggle="yes">-H. pylori</italic> IgG</td><td align="char" char=".">0.195</td><td align="char" char=".">18.6%</td><td align="char" char=".">0.118</td><td align="char" char=".">24.7%</td><td align="char" char=".">&#x02212;0.009</td><td align="char" char=".">0.005</td><td align="char" char=".">0.085</td><td align="char" char=".">0.100</td><td align="char" char=".">0.761</td><td align="center">NA</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CagA antibody</td><td align="char" char=".">0.853</td><td align="char" char=".">0%</td><td align="char" char=".">0.880</td><td align="char" char=".">0%</td><td align="char" char=".">&#x02212;0.012</td><td align="char" char=".">0.031</td><td align="char" char=".">0.691</td><td align="char" char=".">0.878</td><td align="char" char=".">0.946</td><td align="center">NA</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CAT antibody</td><td align="char" char=".">0.576</td><td align="char" char=".">0%</td><td align="char" char=".">0.596</td><td align="char" char=".">0%</td><td align="char" char=".">0.018</td><td align="char" char=".">0.023</td><td align="char" char=".">0.438</td><td align="char" char=".">0.623</td><td align="char" char=".">0.388</td><td align="center">NA</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> GroEL antibody</td><td align="char" char=".">0.060</td><td align="char" char=".">31.6%</td><td align="char" char=".">0.057</td><td align="char" char=".">31.6%</td><td align="char" char=".">0.021</td><td align="char" char=".">0.215</td><td align="char" char=".">0.330</td><td align="char" char=".">0.054</td><td align="char" char=".">0.821</td><td align="center">NA</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> OMP antibody</td><td align="char" char=".">0.857</td><td align="char" char=".">0%</td><td align="char" char=".">0.753</td><td align="char" char=".">0%</td><td align="char" char=".">0.033</td><td align="char" char=".">0.018</td><td align="char" char=".">0.086</td><td align="char" char=".">0.748</td><td align="char" char=".">0.934</td><td align="center">NA</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> UREA antibody</td><td align="char" char=".">0.850</td><td align="char" char=".">0%</td><td align="char" char=".">0.750</td><td align="char" char=".">0%</td><td align="char" char=".">0.035</td><td align="char" char=".">0.019</td><td align="char" char=".">0.091</td><td align="char" char=".">0.754</td><td align="char" char=".">0.227</td><td align="center">NA</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> VacA antibody</td><td align="char" char=".">0.156</td><td align="char" char=".">22.0%</td><td align="char" char=".">0.086</td><td align="char" char=".">28.4%</td><td align="char" char=".">0.050</td><td align="char" char=".">0.028</td><td align="char" char=".">0.081</td><td align="char" char=".">0.090</td><td align="char" char=".">0.904</td><td align="center">NA</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0005"><label>Table 5.</label><caption><p>Reverse MR of serum <italic toggle="yes">H. pylori</italic> antibodies with IgAN.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left"><break/>Exposure</th><th align="center">Method</th><th align="center">SNPs</th><th align="center">&#x000a0;</th><th align="center">OR(95%CI)</th><th align="center"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody valign="top"><tr><td align="left"><italic toggle="yes">Anti-H. pylori</italic> IgG</td><td align="left">Inverse variance weighted</td><td align="char" char=".">28</td><td rowspan="21" align="left">
<inline-graphic xlink:href="IRNF_A_2371055_ILG0002_B.jpg" content-type="black-white"/>
</td><td align="char" char=".">0.992(0.945&#x02013;1.042)</td><td align="char" char=".">0.759</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">28</td><td align="char" char=".">1.092(0.974&#x02013;1.225)</td><td align="char" char=".">0.145</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">28</td><td align="char" char=".">0.968(0.906&#x02013;1.033)</td><td align="char" char=".">0.328</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CagA antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">27</td><td align="char" char=".">0.992(0.745&#x02013;1.320)</td><td align="char" char=".">0.955</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">27</td><td align="char" char=".">1.137(0.551&#x02013;2.347)</td><td align="char" char=".">0.732</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">27</td><td align="char" char=".">0.992(0.745&#x02013;1.320)</td><td align="char" char=".">0.796</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> CAT antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">28</td><td align="char" char=".">1.099(0.882&#x02013;1.369)</td><td align="char" char=".">0.402</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">28</td><td align="char" char=".">0.903(0.529&#x02013;1.542)</td><td align="char" char=".">0.712</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">28</td><td align="char" char=".">1.027(0.747&#x02013;1.413)</td><td align="char" char=".">0.869</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> GroEL antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">28</td><td align="char" char=".">1.024(0.836&#x02013;1.254)</td><td align="char" char=".">0.820</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">28</td><td align="char" char=".">0.815(0.497&#x02013;1.336)</td><td align="char" char=".">0.425</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">28</td><td align="char" char=".">1.045(0.817&#x02013;1.336)</td><td align="char" char=".">0.727</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> OMP antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">28</td><td align="char" char=".">0.993(0.836&#x02013;1.181)</td><td align="char" char=".">0.940</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">28</td><td align="char" char=".">0.696(0.454&#x02013;1.067)</td><td align="char" char=".">0.108</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">28</td><td align="char" char=".">0.960(0.759&#x02013;1.213)</td><td align="char" char=".">0.730</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> UREA antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">28</td><td align="char" char=".">1.111(0.923&#x02013;1.337)</td><td align="char" char=".">0.267</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">28</td><td align="char" char=".">0.766(0.486&#x02013;1.206)</td><td align="char" char=".">0.260</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">28</td><td align="char" char=".">0.958(0.741&#x02013;1.238)</td><td align="char" char=".">0.742</td></tr><tr><td align="left"><italic toggle="yes">H. pylori</italic> VacA antibody</td><td align="left">Inverse variance weighted</td><td align="char" char=".">27</td><td align="char" char=".">0.984(0.753&#x02013;1.284)</td><td align="char" char=".">0.903</td></tr><tr><td align="left">&#x000a0;</td><td align="left">MR Egger</td><td align="char" char=".">27</td><td align="char" char=".">0.567(0.297&#x02013;1.082)</td><td align="char" char=".">0.098</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Weighted median</td><td align="char" char=".">27</td><td align="char" char=".">1.066(0.756&#x02013;1.504)</td><td align="char" char=".">0.714</td></tr></tbody></table><table-wrap-foot><fn id="TF3"><p>OR: odds ratio; LCl: lower confidence interval; UCI: upper confidence interval; IgAN: IgA nephropathy.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" disp-level="1" id="S0004"><title>Discussion</title><p>To the best of our knowledge, this is the first MR study to focus on a causal relationship between <italic toggle="yes">H. pylori</italic> and IgAN. The results of our analysis showed no evidence to support a causal relationship between <italic toggle="yes">H. pylori</italic> infection and increased IgAN, which contradicts the results of some previous experiments. On this basis, we added a reverse MR analysis to explore whether <italic toggle="yes">H. pylori</italic> infection was associated with the occurrence of IgAN, but still obtained negative results.</p><p>IgG antibodies are a common test for detecting <italic toggle="yes">H. pylori</italic> infection, and in a study of <italic toggle="yes">H. pylori</italic> infection in adolescents the sensitivity and specificity of IgG antibody testing were found to be 91.2% and 97.4%, respectively [<xref rid="CIT0014" ref-type="bibr">14</xref>]. CagA is the coding product of the <italic toggle="yes">H. pylori</italic> CagA pathogenic island gene, which is present in most <italic toggle="yes">H. pylori</italic>-infected patients with IgAN [<xref rid="CIT0015" ref-type="bibr">15</xref>]. It promotes glomerular plasma cell proliferation and extracellular matrix secretion by inhibiting apoptotic signaling pathways, and can also lead to severe inflammatory responses in the host [<xref rid="CIT0016" ref-type="bibr">16</xref>]. VacA is a toxin protein secreted by <italic toggle="yes">H. pylori</italic> [<xref rid="CIT0017" ref-type="bibr">17</xref>], and it can cause morphological alterations, such as vacuolization, apoptosis, cytoskeletal rearrangement, and even cell death [<xref rid="CIT0018" ref-type="bibr">18</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref>]. GroEL is a homolog of heat shock protein (HSP 60) in prokaryotes, which is an important pathogenesis-associated antigenic component, and its main function is to promote protein transport, complete the correct folding and restore the natural conformation. Previous studies have shown that more than 80% of the <italic toggle="yes">H. pylori</italic>-infected population produces <italic toggle="yes">H. pylori</italic> GroEL antibodies [<xref rid="CIT0020" ref-type="bibr">20</xref>,<xref rid="CIT0021" ref-type="bibr">21</xref>]. Serum <italic toggle="yes">H. pylori</italic> antibody test is a commonly used method for detecting <italic toggle="yes">H. pylori</italic> infection, but it is not the gold standard for <italic toggle="yes">H. pylori</italic> infection, which may lead to inconsistent results in detecting the association between the two by different methods. In this study, we used Anti-<italic toggle="yes">H. pylori</italic> IgG antibody, <italic toggle="yes">H. pylori</italic> CagA antibody, <italic toggle="yes">H. pylori</italic> CAT antibody, <italic toggle="yes">H. pylori</italic> GroEL antibody, <italic toggle="yes">H. pylori</italic> OMP antibody, <italic toggle="yes">H. pylori</italic> UREA antibody, <italic toggle="yes">H. pylori</italic> VacA antibody as exposure factors to maximize the application of GWAS data related to <italic toggle="yes">H. pylori</italic> infection, and a significant causal relationship between <italic toggle="yes">H. pylori</italic> infection and IgAN was still not detected, and more substantial evidence is needed to elucidate the role of <italic toggle="yes">H. pylori</italic> infection in the role of IgAN.</p><p>Previous studies have shown some association between <italic toggle="yes">H. pylori</italic> infection and IgAN, with patients with IgAN having higher serum <italic toggle="yes">H. pylori</italic> antibodies compared to controls without renal disease [<xref rid="CIT0022" ref-type="bibr">22</xref>], and a significantly higher prevalence of type I <italic toggle="yes">H. pylori</italic> infection in patients with IgAN compared to controls (44.4 vs. 28.3%, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.040). Patients with type I <italic toggle="yes">H. pylori</italic> infection had higher levels of systolic blood pressure, 24-h proteinuria, and blood urea nitrogen compared to uninfected patients [<xref rid="CIT0013" ref-type="bibr">13</xref>]. The pathogenesis may be that <italic toggle="yes">H. pylori</italic> infection induces the expression of inflammatory cytokines, chemokines, growth factors, etc., which leads to an inflammatory microenvironment, damage to the endothelial structure of the renal vasculature, and an increase in the urinary albumin excretion rate. In addition, <italic toggle="yes">H. pylori</italic> infection induces the release of cytokines and vasoactive substances, such as C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-&#x003b1;), interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 8 (IL-8), and heat shock proteins (HSPs), which elicit both local and systemic immune responses and exacerbate microvascular injury [<xref rid="CIT0023" ref-type="bibr">23</xref>]. Hypersensitive C-reactive protein (hs-CRP) is increased after <italic toggle="yes">H. pylori</italic> infection [<xref rid="CIT0024" ref-type="bibr">24</xref>], and high levels of CRP are considered to be one of the key risk factors for chronic kidney injury [<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0025" ref-type="bibr">25</xref>,<xref rid="CIT0026" ref-type="bibr">26</xref>]. TNF-&#x003b1; induces the expression of vascular endothelial cell adhesion molecules, leading to the proliferation of glomerular tunica albuginea cells [<xref rid="CIT0027" ref-type="bibr">27</xref>]. Therefore, <italic toggle="yes">H. pylori</italic> infection can lead to chronic kidney damage or accelerate renal impairment by causing a systemic inflammatory response [<xref rid="CIT0028" ref-type="bibr">28</xref>,<xref rid="CIT0029" ref-type="bibr">29</xref>].</p><p>Multiple potential biological mechanisms may explain the relationship between <italic toggle="yes">H. pylori</italic> infection and IgAN. <italic toggle="yes">H. pylori</italic> stimulates acute and chronic inflammatory immune responses, and IgAN patients are more prone to develop a robust mucosal immune response upon exposure to <italic toggle="yes">H. pylori</italic>. Higher levels of IgA1 bound to lectin in IgAN patients with mucosal <italic toggle="yes">H. pylori</italic> infection suggest that mucosal <italic toggle="yes">H. pylori</italic> infection induces underglycosylation of IgA1 [<xref rid="CIT0030" ref-type="bibr">30</xref>]. This incomplete glycosylation of IgA1 may act as a self-antigen, triggering autoantibody production [<xref rid="CIT0031" ref-type="bibr">31</xref>]. It has been reported that circulating immune complexes containing IgA autoantibodies, with the possible assistance of IgA receptors and combined with polymerized galactose-deficient IgA1 (Gd-IgA1), are deposited in the glomerular mesangial zone, leading to glomerular mesangial cell proliferation, extracellular matrix accumulation, overproduction of cytokine and chemokine, and glomerular injury. Previous studies have also shown elevated levels of Gd-IgA1 in <italic toggle="yes">H. pylori</italic>-infected patients with IgAN [<xref rid="CIT0013" ref-type="bibr">13</xref>]. One study showed that of 71 antibodies that reacted with <italic toggle="yes">H. pylori</italic> in the gastric mucosa, 11 cross-reacted with renal tubular cells [<xref rid="CIT0032" ref-type="bibr">32</xref>]. Another report found that monoclonal anti-<italic toggle="yes">H. pylori</italic> and anti-CagA antibodies exclusively reacted with renal tubules. CagA, a key virulence factor of <italic toggle="yes">H. pylori,</italic> is implicated in the pathogenesis of IgAN by stimulating the proliferation of the B-cell line DAKIKI cells (a surface IgA 1-positive human B-lymphoma cell line), which produce IgA1 and exhibit underglycosylation of IgA1. CagA promotes cell proliferation at low concentrations and inhibits it at high concentrations [<xref rid="CIT0028" ref-type="bibr">28</xref>].</p><p>In patients with IgAN, acute pharyngeal tonsillitis is the most common extrarenal clinical manifestation [<xref rid="CIT0033" ref-type="bibr">33</xref>]. The onset of pharyngeal tonsillitis is closely related to hematuria and proteinuria [<xref rid="CIT0034" ref-type="bibr">34</xref>]. Specific pathogens can directly deposit in renal tissue, participating in the onset and progression of IgAN. In the renal tissue of IgAN patients, various pathogens can be detected, including bacteria such as Haemophilus parainfluenzae, Staphylococcus aureus, as well as viruses like cytomegalovirus and EB virus [<xref rid="CIT0035" ref-type="bibr">35&#x02013;39</xref>]. Two recent Japanese studies have reported finding <italic toggle="yes">H. pylori</italic> in the palatal tonsils of all studied IgAN patients, with 78.6% testing positive for CagA. This suggests that <italic toggle="yes">H. pylori</italic> in the tonsils may be a pathogenic agent for IgAN [<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0014" ref-type="bibr">14</xref>]. This phenomenon is thought to result from the substantial IgA system response to infectious antigens present in the tonsils. Seventy percent of IgAN patients exhibit positive staining for anti <italic toggle="yes">H. pylori</italic> antibodies, which are distributed in a granular pattern along the glomerular capillary wall [<xref rid="CIT0040" ref-type="bibr">40</xref>]. It is hypothesized that <italic toggle="yes">H. pylori</italic> and anti <italic toggle="yes">H. pylori</italic> IgA antibodies form an immune complex in the tonsils, circulate through the bloodstream, and deposit in the glomeruli. However, further mechanistic research is warranted.</p><p>Recently, Some studies have suggested that <italic toggle="yes">H. pylori</italic> is more prevalent in patients with IgAN, but the current view remains controversial [<xref rid="CIT0011" ref-type="bibr">11</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref>]. Observational studies are subject to unavoidable confounding factors, and reverse causality cannot be ruled out. In addition, the sample sizes of these studies are small, so the results are somewhat biased and the level of evidence is lower than that of RCT studies. The causal relationship between the two still needs to be further verified by RCTs with large sample sizes. The use of RCTs to determine reliable and accurate causality can be very expensive and unethical, whereas MR has no research costs or ethical issues, and the random assignment of IV alleles at conception makes the MR method a &#x02018;naturally RCT,&#x02019; making MR a good tool for causal inference. In conclusion, we used a two-sample bidirectional MR analysis to investigate the relationship between <italic toggle="yes">H. pylori</italic> infection and IgAN. This MR study has several strengths. First, the seven phenotypic summary statistics associated with <italic toggle="yes">H. pylori</italic> infection were utilized to expand the list of <italic toggle="yes">H. pylori</italic> infections, and the use of the most recent and complete GWAS data as IVs maximized statistical efficacy. Second, the application of strict IVs prerequisites and bidirectional two-sample MR analysis ensured that confounders were less biased and excluded the effect of reverse causality. Finally, the large sample size of the study and the sample populations used were all European, avoiding bias from population heterogeneity. We refined the bidirectional magnetic resonance analysis to exclude the interference of reverse causality, and the results were reliable. Although our study obtained significant results, some limitations should be noted: first, to ensure that the working variables were present in all study populations, we set the IVs significance threshold of 1e-5 instead of the classical 5e-8. Second, the serum <italic toggle="yes">H. pylori</italic> antibody test is not considered the gold standard for diagnosing <italic toggle="yes">H. pylori</italic> infection. However, current GWAS data do not incorporate histological, molecular, or breath test data for <italic toggle="yes">H. pylori</italic> infection, so serum <italic toggle="yes">H. pylori</italic> antibodies are often used as an exposure factor for MR study [<xref rid="CIT0041" ref-type="bibr">41</xref>, <xref rid="CIT0042" ref-type="bibr">42</xref>]. Third, the study population included only individuals of European origin; therefore, the results of this study may not be generalized to populations of other ancestries. The prevalence of IgAN is highest in Asia and the Pacific Rim, followed by European[<xref rid="CIT0006" ref-type="bibr">6</xref>], and the genetic risk alleles for IgAN are reportedly more common in Chinese individuals than in Europeans[<xref rid="CIT0043" ref-type="bibr">43</xref>]. However, our search did not yield specific GWAS data on <italic toggle="yes">H. pylori</italic> infection in Asian populations. Consequently, more studies are needed in the future to determine whether there are any regional or racial differences in the results of MR analyses. Fourth, there was some sample overlap between exposure factors and outcomes, however, the calculated maximum overlap was &#x0003c;1%, which did not affect the results obtained from the analysis. Fifth, due to the use of summary level data, we are unable to analyze non-linear correlations or stratified effects. Finally, the sample size of <italic toggle="yes">H. pylori</italic> CagA is relatively small, which may diminish the statistical ability to detect causal relationships. If more comprehensive data become available, future research will continue to explore the causal relationship between <italic toggle="yes">H. pylori</italic> CagA antibody and IgAN to verify the reliability of the results.</p></sec><sec sec-type="conclusions" disp-level="1" id="S0005"><title>Conclusion</title><p>Our study using MR showed no evidence of a significant causal relationship between genetically predicted <italic toggle="yes">H. pylori</italic> infection and IgAN. Further longitudinal studies using more adequate data and populations from different sources are still needed to explore causality, refine subgroup stratification, and elucidate how <italic toggle="yes">H. pylori</italic> infection affects the onset or progression of IgAN.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM9141" position="float" content-type="local-data"><caption><title>Supplemental Material</title></caption><media xlink:href="IRNF_A_2371055_SM9141.docx"/></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We thank all the participants in this study. We thank all contributors to the GWAS database.</p></ack><sec disp-level="1" id="S0006"><title>Authors&#x02019; contributions</title><p>S.J. designed the study and wrote the manuscript. L.L. performed the data extraction. J.L. and J.P. analyzed and interpreted the data. X.Q. performed the project management, comparison and review. All authors read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" disp-level="1" id="S0007"><title>Disclosure statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.</p></sec><sec sec-type="data-availability" disp-level="1" id="S0008"><title>Data availability statement</title><p>The data we used are publicly available summary statistics and can be obtained upon reasonable request.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jones</surname>
<given-names>NL</given-names></string-name>, <string-name><surname>Koletzko</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Goodman</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Joint ESPGHAN/NASPGHAN Guidelines for the management of Helicobacter pylori in children and adolescents (Update 2016)</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2017</year>;<volume>64</volume>(<issue>6</issue>):<fpage>1</fpage>&#x02013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MPG.0000000000001594</pub-id>.<pub-id pub-id-type="pmid">27253663</pub-id>
</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Niknam</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Barfei</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mahmoudi</surname>
<given-names>L.</given-names></string-name></person-group>
<article-title>Helicobacter pylori, &#x000ad;endoscopic, and histologic features among kidney transplant candidates in Southern Iran</article-title>. <source>Infect Drug Resist</source>. <year>2019</year>;<volume>12</volume>:<fpage>3687</fpage>&#x02013;<lpage>3693</lpage>.<pub-id pub-id-type="pmid">31819550</pub-id>
</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Association between Helicobacter pylori infection and kidney damage in patients with peptic ulcer</article-title>. <source>Ren Fail</source>. <year>2019</year>;<volume>41</volume>(<issue>1</issue>):<fpage>1028</fpage>&#x02013;<lpage>1034</lpage>. doi: <pub-id pub-id-type="doi">10.1080/0886022X.2019.1683029</pub-id>.<pub-id pub-id-type="pmid">31755342</pub-id>
</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shin</surname>
<given-names>SP</given-names></string-name>, <string-name><surname>Bang</surname>
<given-names>CS</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JJ</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Helicobacter pylori &#x000ad;infection in patients with chronic kidney disease: a &#x000ad;systematic review and meta-analysis</article-title>. <source>Gut Liver</source>. <year>2019</year>;<volume>13</volume>(<issue>6</issue>):<fpage>628</fpage>&#x02013;<lpage>641</lpage>. doi: <pub-id pub-id-type="doi">10.5009/gnl18517</pub-id>.<pub-id pub-id-type="pmid">30970438</pub-id>
</mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pattrapornpisut</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Avila-Casado</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Reich</surname>
<given-names>HN.</given-names></string-name></person-group>
<article-title>IgA nephropathy: core Curriculum 2021</article-title>. <source>Am J Kidney Dis</source>. <year>2021</year>;<volume>78</volume>(<issue>3</issue>):<fpage>429</fpage>&#x02013;<lpage>441</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.ajkd.2021.01.024</pub-id>.<pub-id pub-id-type="pmid">34247883</pub-id>
</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schena</surname>
<given-names>FP</given-names></string-name>, <string-name><surname>Nistor</surname>
<given-names>I.</given-names></string-name></person-group>
<article-title>Epidemiology of IgA nephropathy: a global perspective</article-title>. <source>Semin Nephrol</source>. <year>2018</year>;<volume>38</volume>(<issue>5</issue>):<fpage>435</fpage>&#x02013;<lpage>442</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.semnephrol.2018.05.013</pub-id>.<pub-id pub-id-type="pmid">30177015</pub-id>
</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Galla</surname>
<given-names>JH.</given-names></string-name></person-group>
<article-title>IgA nephropathy</article-title>. <source>Kidney Int</source>. <year>1995</year>;<volume>47</volume>(<issue>2</issue>):<fpage>377</fpage>&#x02013;<lpage>387</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ki.1995.50</pub-id>.<pub-id pub-id-type="pmid">7723227</pub-id>
</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reich</surname>
<given-names>HN</given-names></string-name>, <string-name><surname>Troyanov</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Scholey</surname>
<given-names>JW</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Remission of proteinuria improves prognosis in IgA nephropathy</article-title>. <source>J Am Soc Nephrol</source>. <year>2007</year>;<volume>18</volume>(<issue>12</issue>):<fpage>3177</fpage>&#x02013;<lpage>3183</lpage>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2007050526</pub-id>.<pub-id pub-id-type="pmid">17978307</pub-id>
</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>D&#x02019;Amico</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Colasanti</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Belgioioso</surname>
<given-names>GBd</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients</article-title>. <source>Semin Nephrol</source>. <year>1987</year>;<volume>7</volume>(<issue>4</issue>):<fpage>355</fpage>&#x02013;<lpage>358</lpage>.<pub-id pub-id-type="pmid">3445015</pub-id>
</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moriyama</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Iwasaki</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan</article-title>. <source>PLOS One</source>. <year>2014</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e91756</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0091756</pub-id>.<pub-id pub-id-type="pmid">24658533</pub-id>
</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kusano</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Inokuchi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fujimoto</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Coccoid Helicobacter pylori exists in the palatine tonsils of patients with IgA nephropathy</article-title>. <source>J Gastroenterol</source>. <year>2010</year>;<volume>45</volume>(<issue>4</issue>):<fpage>406</fpage>&#x02013;<lpage>412</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00535-009-0169-9</pub-id>.<pub-id pub-id-type="pmid">19997853</pub-id>
</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kong</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Association of H. pylori infection with chronic kidney disease among Chinese adults</article-title>. <source>Int Urol Nephrol</source>. <year>2017</year>;<volume>49</volume>(<issue>5</issue>):<fpage>845</fpage>&#x02013;<lpage>850</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11255-016-1498-2</pub-id>.<pub-id pub-id-type="pmid">28044235</pub-id>
</mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>XZ</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>YM</given-names></string-name>, <string-name><surname>Jia</surname>
<given-names>NY</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy</article-title>. <source>Ren Fail</source>. <year>2020</year>;<volume>42</volume>(<issue>1</issue>):<fpage>539</fpage>&#x02013;<lpage>546</lpage>. doi: <pub-id pub-id-type="doi">10.1080/0886022X.2020.1772295</pub-id>.<pub-id pub-id-type="pmid">32524871</pub-id>
</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ueda</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Okuda</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nishiyama</surname>
<given-names>T</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diagnostic accuracy of the E-plate serum antibody test kit in detecting Helicobacter pylori infection among Japanese children</article-title>. <source>J Epidemiol</source>. <year>2014</year>;<volume>24</volume>(<issue>1</issue>):<fpage>47</fpage>&#x02013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.2188/jea.JE20130078</pub-id>.<pub-id pub-id-type="pmid">24240631</pub-id>
</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname>
<given-names>TT</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>HL</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Helicobacter pylori participates in the pathogenesis of IgA nephropathy</article-title>. <source>Ren Fail</source>. <year>2016</year>;<volume>38</volume>(<issue>9</issue>):<fpage>1398</fpage>&#x02013;<lpage>1404</lpage>. doi: <pub-id pub-id-type="doi">10.1080/0886022X.2016.1216713</pub-id>.<pub-id pub-id-type="pmid">27764998</pub-id>
</mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>RZ</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>CagA promotes proliferation and secretion of extracellular matrix by inhibiting signaling pathway of apoptosis in rat glomerular mesangial cells</article-title>. <source>Ren Fail</source>. <year>2016</year>;<volume>38</volume>(<issue>3</issue>):<fpage>458</fpage>&#x02013;<lpage>464</lpage>. doi: <pub-id pub-id-type="doi">10.3109/0886022X.2016.1138831</pub-id>.<pub-id pub-id-type="pmid">26837331</pub-id>
</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chmiela</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kupcinskas</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Review: pathogenesis of Helicobacter pylori infection</article-title>. <source>Helicobacter</source>. <year>2019</year>;<volume>24</volume>(<issue>S1</issue>):<fpage>e12638</fpage>. doi: <pub-id pub-id-type="doi">10.1111/hel.12638</pub-id>.<pub-id pub-id-type="pmid">31486234</pub-id>
</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Galmiche</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rassow</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Doye</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The N-terminal 34&#x02009;kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release</article-title>. <source>Embo j</source>. <year>2000</year>;<volume>19</volume>(<issue>23</issue>):<fpage>6361</fpage>&#x02013;<lpage>6370</lpage>. doi: <pub-id pub-id-type="doi">10.1093/emboj/19.23.6361</pub-id>.<pub-id pub-id-type="pmid">11101509</pub-id>
</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Molinari</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Salio</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Galli</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VacA</article-title>. <source>J Exp Med</source>. <year>1998</year>;<volume>187</volume>(<issue>1</issue>):<fpage>135</fpage>&#x02013;<lpage>140</lpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.187.1.135</pub-id>.<pub-id pub-id-type="pmid">9419220</pub-id>
</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fern&#x000e1;ndez-de-Larrea</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Michel</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Romero</surname>
<given-names>B</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Antibody reactivity against Helicobacter pylori proteins in a sample of the Spanish adult population in 2008&#x02013;2013</article-title>. <source>Helicobacter</source>. <year>2017</year>;<volume>22</volume>(<issue>5</issue>):e12401. doi: <pub-id pub-id-type="doi">10.1111/hel.12401</pub-id>.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Michel</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pawlita</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Boeing</surname>
<given-names>H</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Helicobacter pylori antibody patterns in Germany: a cross-sectional population study</article-title>. <source>Gut Pathog</source>. <year>2014</year>;<volume>6</volume>(<issue>1</issue>):<fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1757-4749-6-10</pub-id>.<pub-id pub-id-type="pmid">24782915</pub-id>
</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barratt</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bailey</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Buck</surname>
<given-names>KS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy</article-title>. <source>Am J Kidney Dis</source>. <year>1999</year>;<volume>33</volume>(<issue>6</issue>):<fpage>1049</fpage>&#x02013;<lpage>1057</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0272-6386(99)70141-1</pub-id>.<pub-id pub-id-type="pmid">10352192</pub-id>
</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanbay</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kasapoglu</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Akcay</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>An occult risk factor for proteinuria: helicobacter pylori infection</article-title>. <source>Med Hypotheses</source>. <year>2007</year>;<volume>69</volume>(<issue>3</issue>):<fpage>709</fpage>&#x02013;<lpage>710</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mehy.2007.01.010</pub-id>.</mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rahmani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Moradkhani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hafezi Ahmadi</surname>
<given-names>MR</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Association between serum levels of high sensitive C-reactive protein and inflammation activity in chronic gastritis patients</article-title>. <source>Scand J Gastroenterol</source>. <year>2016</year>;<volume>51</volume>(<issue>5</issue>):<fpage>531</fpage>&#x02013;<lpage>537</lpage>. doi: <pub-id pub-id-type="doi">10.3109/00365521.2015.1102318</pub-id>.<pub-id pub-id-type="pmid">26758551</pub-id>
</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Testerman</surname>
<given-names>TL</given-names></string-name>, <string-name><surname>Morris</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment</article-title>. <source>WJG</source>. <year>2014</year>;<volume>20</volume>(<issue>36</issue>):<fpage>12781</fpage>&#x02013;<lpage>12808</lpage>. doi: <pub-id pub-id-type="doi">10.3748/wjg.v20.i36.12781</pub-id>.<pub-id pub-id-type="pmid">25278678</pub-id>
</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Umit</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Umit</surname>
<given-names>EG.</given-names></string-name></person-group>
<article-title>Helicobacter pylori and mean platelet volume: a relation way before &#x00131;mmune thrombocytopenia?</article-title>
<source>Eur Rev Med Pharmacol Sci</source>. <year>2015</year>;<volume>19</volume>(<issue>15</issue>):<fpage>2818</fpage>&#x02013;<lpage>2823</lpage>.<pub-id pub-id-type="pmid">26241535</pub-id>
</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sulikowska</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Rutkowski</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Marsza&#x00142;ek</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The role of interstitial changes in the progression of chronic kidney disease</article-title>. <source>Postepy Hig Med Dosw</source>. <year>2015</year>;<volume>69</volume>:<fpage>830</fpage>&#x02013;<lpage>837</lpage>. doi: <pub-id pub-id-type="doi">10.5604/17322693.1162570</pub-id>.</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>FG</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>XS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>CagA, a major virulence factor of Helicobacter pylori, promotes the production and underglycosylation of IgA1 in DAKIKI cells</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2014</year>;<volume>444</volume>(<issue>2</issue>):<fpage>276</fpage>&#x02013;<lpage>281</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2014.01.050</pub-id>.<pub-id pub-id-type="pmid">24462875</pub-id>
</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname>
<given-names>SY</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>JH</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Association between Helicobacter pylori infection and the subsequent risk of end-stage renal disease: a nationwide population-based cohort study</article-title>. <source>Int J Clin Pract</source>. <year>2015</year>;<volume>69</volume>(<issue>5</issue>):<fpage>604</fpage>&#x02013;<lpage>610</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ijcp.12602</pub-id>.<pub-id pub-id-type="pmid">25644865</pub-id>
</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Molyneux</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Feehally</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy</article-title>. <source>J Am Soc Nephrol</source>. <year>2006</year>;<volume>17</volume>(<issue>12</issue>):<fpage>3520</fpage>&#x02013;<lpage>3528</lpage>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2006060658</pub-id>.<pub-id pub-id-type="pmid">17093066</pub-id>
</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Suzuki</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kiryluk</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Novak</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The pathophysiology of IgA nephropathy</article-title>. <source>J Am Soc Nephrol</source>. <year>2011</year>;<volume>22</volume>(<issue>10</issue>):<fpage>1795</fpage>&#x02013;<lpage>1803</lpage>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2011050464</pub-id>.<pub-id pub-id-type="pmid">21949093</pub-id>
</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ko</surname>
<given-names>GH</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>HB</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>MK</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Monoclonal antibodies against Helicobacter pylori cross-react with human tissue</article-title>. <source>Helicobacter</source>. <year>1997</year>;<volume>2</volume>(<issue>4</issue>):<fpage>210</fpage>&#x02013;<lpage>215</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1523-5378.1997.tb00090.x</pub-id>.<pub-id pub-id-type="pmid">9421126</pub-id>
</mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Caraman</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Azoulay</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kessler</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<part-title>Mucosal infections and allergy in IgA nephropathy. A retrospective study</part-title>. <source>Association des N&#x000e9;phrologues de l&#x02019;Est de la France</source>. <publisher-name>Contrib Nephrol</publisher-name>. <year>1993</year>;<volume>104</volume>:<fpage>24</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>B&#x000e9;n&#x000e9;</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Ligny</surname>
<given-names>BHd</given-names></string-name>, <string-name><surname>Kessler</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Tonsils in IgA nephropathy</article-title>. <source>Contrib Nephrol</source>. <year>1993</year>;<volume>104</volume>:<fpage>153</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">8325026</pub-id>
</mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>WS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cytomegalovirus is not specifically associated with immunoglobulin A nephropathy</article-title>. <source>J Am Soc Nephrol</source>. <year>1994</year>;<volume>4</volume>(<issue>8</issue>):<fpage>1623</fpage>&#x02013;<lpage>1626</lpage>. doi: <pub-id pub-id-type="doi">10.1681/ASN.V481623</pub-id>.<pub-id pub-id-type="pmid">8025236</pub-id>
</mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Suzuki</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Nakatomi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Sato</surname>
<given-names>H</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy</article-title>. <source>Lancet</source>. <year>1994</year>;<volume>343</volume>(<issue>8888</issue>):<fpage>12</fpage>&#x02013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(94)90875-3</pub-id>.<pub-id pub-id-type="pmid">7905040</pub-id>
</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharmin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shimizu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Hagiwara</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Staphylococcus aureus antigens induce IgA-type glomerulonephritis in Balb/c mice</article-title>. <source>J Nephrol</source>. <year>2004</year>;<volume>17</volume>(<issue>4</issue>):<fpage>504</fpage>&#x02013;<lpage>511</lpage>.<pub-id pub-id-type="pmid">15372411</pub-id>
</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iwama</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Horikoshi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shirato</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Epstein-Barr virus detection in kidney biopsy specimens &#x000ad;correlates with glomerular mesangial injury</article-title>. <source>Am J Kidney Dis</source>. <year>1998</year>;<volume>32</volume>(<issue>5</issue>):<fpage>785</fpage>&#x02013;<lpage>793</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0272-6386(98)70134-9</pub-id>.<pub-id pub-id-type="pmid">9820448</pub-id>
</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tomino</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yagame</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Omata</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A case of IgA nephropathy associated with adeno- and herpes simplex viruses</article-title>. <source>Nephron</source>. <year>1987</year>;<volume>47</volume>(<issue>4</issue>):<fpage>258</fpage>&#x02013;<lpage>261</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000184520</pub-id>.<pub-id pub-id-type="pmid">2827043</pub-id>
</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nagashima</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Maeda</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Yuda</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Helicobacter pylori antigen in the glomeruli of patients with membranous nephropathy</article-title>. <source>Virchows Arch</source>. <year>1997</year>;<volume>431</volume>(<issue>4</issue>):<fpage>235</fpage>&#x02013;<lpage>239</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s004280050094</pub-id>.<pub-id pub-id-type="pmid">9368660</pub-id>
</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>X</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Causality of Helicobacter pylori infection on eosinophilic esophagitis and potential pathogenesis: a Mendelian randomization study</article-title>. <source>Front Immunol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1365604</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2024.1365604</pub-id>.<pub-id pub-id-type="pmid">38779684</pub-id>
</mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Causal associations between Helicobacter pylori infection and pregnancy and neonatal outcomes: a two-sample Mendelian randomization study</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2024</year>;<volume>14</volume>:<fpage>1343499</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2024.1343499</pub-id>.<pub-id pub-id-type="pmid">38558850</pub-id>
</mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yeo</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Goh</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Barratt</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Is immunoglobulin A nephropathy different in different ethnic populations?</article-title>
<source>Nephrology</source>. <year>2019</year>;<volume>24</volume>(<issue>9</issue>):<fpage>885</fpage>&#x02013;<lpage>895</lpage>. doi: <pub-id pub-id-type="doi">10.1111/nep.13592</pub-id>.<pub-id pub-id-type="pmid">30977248</pub-id>
</mixed-citation></ref></ref-list></back></article>